Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-κB activation through inhibition of activation of IκBα kinase and Akt in human non-small cell lung carcinoma:: Correlation with suppression of COX-2 synthesis

被引:167
作者
Shishodia, S
Koul, D
Aggarwal, BB
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA
关键词
D O I
10.4049/jimmunol.173.3.2011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The cyclooxygenase 2 (COX-2) inhibitor celecoxib (also called celebrex), approved,for the treatment of colon carcinogenesis, rheumatoid arthritis, and other inflammatory diseases, has been shown to induce apoptosis and inhibit angiogenesis. Because NF-kappaB plays a major role in regulation of apoptosis, angiogenesis, carcinogenesis, and inflammation, we postulated that celecoxib modulates NF-kappaB. In the present study, we investigated the effect of this drug on the activation of NF-kappaB by a wide variety of agents. We found that celecoxib suppressed NF-kappaB activation induced by various carcinogens, including TNF, phorbol ester, okadaic acid, LPS, and IL-1beta. Celecoxib inhibited TNF-induced IkappaBalpha kinase activation, leading to suppression of IkappaBalpha phosphorylation and degradation. Celecoxib suppressed both inducible and constitutive NF-kappaB without cell type specificity. Celecoxib also suppressed p65 phosphorylation and nuclear translocation. Akt activation, which is required for TNF-induced NF-kappaB activation, was also suppressed by this drug. Celecoxib also inhibited the TNF-induced interaction of Akt with IkappaBalpha kinase (IKK). Celecoxib abrogated the NF-kappaB-dependent reporter gene expression activated by TNF, TNF receptor, TNF receptor-associated death domain, TNF receptor-associated factor 2, NF-kappaB-inducing kinase, and IKK, but not that activated by p65. The COX-2 promoter, which is regulated by NF-kappaB, was also inhibited by celecoxib, and this inhibition correlated with suppression of TNF-induced COX-2 expression. Besides NF-kappaB, celecoxib also suppressed TNF-induced JNK, p38 MAPK, and ERK activation. Thus, overall, our results indicate that celecoxib inhibits NF-kappaB activation through inhibition of IKK and Akt activation, leading to down-regulation of synthesis of COX-2 and other genes needed for inflammation, proliferation, and carcinogenesis.
引用
收藏
页码:2011 / 2022
页数:12
相关论文
共 58 条
[1]  
Abou-Issa HM, 2001, ANTICANCER RES, V21, P3425
[2]   Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line [J].
Arico, S ;
Pattingre, S ;
Bauvy, C ;
Gane, P ;
Barbat, A ;
Codogno, P ;
Ogier-Denis, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (31) :27613-27621
[3]  
BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809
[4]  
Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585
[5]   Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin [J].
Chun, KS ;
Kim, SH ;
Song, YS ;
Surh, YJ .
CARCINOGENESIS, 2004, 25 (05) :713-722
[6]   Clinical pharmacokinetics and pharmacodynamics of celecoxib - A selective cyclo-oxygenase-2 inhibitor [J].
Davies, NM ;
McLachlan, AJ ;
Day, RO ;
Williams, KM .
CLINICAL PHARMACOKINETICS, 2000, 38 (03) :225-242
[7]   Protein kinase C-ζ regulates transcription of the matrix metalloproteinase-9 gene induced by IL-1 and TNF-α in glioma cells via NF-κB [J].
Estève, PO ;
Chicoine, É ;
Robledo, O ;
Aoudjit, F ;
Descoteaux, A ;
Potworowski, EF ;
St-Pierre, Y .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (38) :35150-35155
[8]   COX-2-specific inhibitors -: the emergence of a new class of analgesic and anti-inflammatory drugs [J].
Everts, B ;
Währborg, P ;
Hedner, T .
CLINICAL RHEUMATOLOGY, 2000, 19 (05) :331-343
[9]   INDUCIBLE PHOSPHORYLATION OF I-KAPPA-B-ALPHA IS NOT SUFFICIENT FOR ITS DISSOCIATION FROM NF-KAPPA-B AND IS INHIBITED BY PROTEASE INHIBITORS [J].
FINCO, TS ;
BEG, AA ;
BALDWIN, AS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (25) :11884-11888
[10]  
Fischer SM, 1999, MOL CARCINOGEN, V25, P231